Quad Technologies Inc., a Woburn, MA-based developer of a novel cell separation technology, raised an undisclosed amount of funding as a part of its Series A round.
Backers included Keswick Ventures and others.
The company will use the funds to accelerate development of cell processing technologies for translational medicine applications.
Established in 2013 and led by CEO Sean Kevlahan, Quad Technologies is a developer of novel cell separation technology for the binding and releasing of rare cells. Its MagCloudz™ Streptavidin Cell Separation Kit, the first commercially available product incorporating the proprietary QuickGel™ technology, enables cell separation with magnetic particle dissociation, resulting in complete label free cells for applications including T Cell purification, stem cell isolation, and circulating tumor cell (CTC) separation.